Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07505303 · ClinicalTrials.gov registry record · Phase 2
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
A Phase 2 study, sponsored by Eccogene.
- Active
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
NCT07505303 is a Phase 2 study that is active but no longer recruiting, run by Eccogene. The registered enrollment target is 151 participants.
The verdict
NCT07505303, a Phase 2 study, is active but no longer recruiting, sponsored by Eccogene.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
Study Summary
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
Interventions
- DRUG Placebo
- DRUG Semaglutide
- DRUG ECC4703
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2026-03-23 |
| Est. Completion | 2026-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07505303
The ClinicalTrials.gov registry entry for NCT07505303 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eccogene, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07505303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07505303 about?
NCT07505303 is a clinical study titled "MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial". The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction (MRI-PDFF) at Week 20.
What is the current status of trial NCT07505303?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2026-03-23. Estimated completion is 2026-10-15.
What interventions are being tested in trial NCT07505303?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), ECC4703 (DRUG).
Who is sponsoring clinical trial NCT07505303?
This trial is sponsored by Eccogene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.